Effectiveness of Psilocybin on Depression : A Qualitative Study Redhwan Ahmed Al-Naggar, Hisham Alshaikhli, Gwen Erlam Electronic Journal of General Medicine, 2021, 18, (3), em296. doi : 10.29333/ejgm/10862 ABSTRACT Introduction : Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. Objective : The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. Method : A qualitative study was conducted interviewing ten participants currently taking psilocybin while experiencing depression and/or anxiety. Ethical approval was obtained from the University ethics committee. Participants were recruited [...]
Lire la suiteCOVID-19, usage d’alcool et de cannabis Canadian Center on Substance Use and Addiction www.ccsa.ca • www.ccdus.ca Le présent document d’information vient compléter l’infographie COVID-19, usage d’alcool et de cannabis et décrit certains des liens factuels entre la COVID-19 et l’usage d’alcool et de cannabis. Le document s’adresse à un large public, notamment les professionnels de la santé, les décideurs et les chercheurs. Les risques associés à l’usage d’alcool et de cannabis sont plus importants pendant la pandémie de COVID-19. Face à cette menace constante, les Canadiens pourraient vivre des émotions et des situations qui influeront sur leur usage d’alcool et de cannabis, et tout [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteUnique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle Gustavo Gonzalez-Cuevas, Remi Martin-Fardon, Tony M. Kerr, David G. Stouffer, Loren H. Parsons, Dana C. Hammell, Stan L. Banks, Audra L. Stinchcomb and Friedbert Weiss Neuropsychopharmacology, 2018, 43, 2036–2045. Doi : 10.1038/s41386-018-0050-8 Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders. Recently, CBD has also been explored for potential in treating drug addiction. Substance use disorders are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to [...]
Lire la suitePerceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders Toby Lea & Nicole Amada & Henrik Jungaberle & Henrike Schecke & Norbert Scherbaum & Michael Klein Psychopharmacology, 2020. Di : 10.1007/s00213-020-05477-0 Abstract Rationale : The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives : This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease [...]
Lire la suiteTherapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized-Controlled Clinical Trials Juan José Fuentes, Francina Fonseca, Matilde Elices, Magí Farré and Marta Torrens Frontiers in Psychiatry, 2020, Vol 10, Article 943. doi : 10.3389/fpsyt.2019.00943 Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and [...]
Lire la suiteLe cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6. Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]
Lire la suitePsilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734 Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]
Lire la suiteSingle Shot of Ketamine May Herald 'Last Call' for Problem Drinking Deborah Brauser Medscape, December 11, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/922460?src=wnl_tp10n_200116_mscpedit&uac=292598PZ&impID=2238619&faf=1 An experimental treatment that includes a single infusion of ketamine may lead to long-term improvement in problem drinking, new research suggests. In an study of 90 heavy drinkers, those who received a single dose of intravenous (IV) ketamine plus cognitive behavioral therapy (CBT) that focused on reactivating drinking-related "maladaptive reward memories" (MRMs) significantly curbed the urge to drink and reduced alcohol intake compared with those who received the ketamine alone or a placebo infusion. In addition, the combination group reduced their average weekly alcohol consumption by [...]
Lire la suiteSoigner l'alcoolisme et la dépression avec des psychédéliques? Entretien avec David Nutt #RTSsanté , 11 avril 2019 https://www.youtube.com/watch?time_continue=55&v=D8QNY2bdNCk&feature=emb_logo Vidéo en complément du reportage « Le retour des psychédéliques » : https://youtu.be/503cSLA0Z38 Parmi les très nombreux articles cosignés par le Professeur David J. NUTT, du Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom, les références suivantes sont disponibles sur le site du GRECC : Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity, Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. [...]
Lire la suite